Abstract

Objective

Cannabis use disorder (CUD) is associated with an elevated risk for psychiatric disorders and symptoms, contributing to poor health outcomes and increased medical costs. Unfortunately, interventions that simultaneously address cannabis use and co-occurring psychiatric disorders are limited in availability. Targeted digital interventions to reduce cannabis use could be beneficial for patients with psychiatric disorders. Digital interventions could be easily disseminated and used in numerous clinical locations, including outpatient, inpatient, residential, and community psychiatric treatment settings.

Methods

Literature on digital cannabis reduction interventions for persons with psychiatric disorders was examined between April 2021 and June 2021. Articles were obtained from PubMed and PsycINFO databases. English language randomized controlled trials (RCT), feasibility and acceptability studies, pilot studies, and published protocols were included.

Results

There is significant evidence that digital interventions can effectively reduce cannabis use in general, non-clinical populations. However, there is less literature examining interventions for persons living with co-occurring psychiatric illness—most of which is tailored to patients living with chronic psychosis.

Conclusions

There is great need for accessible and tailored digital interventions for co-occurring CUD and psychiatric disorders.

中文翻译：

---

减少合并精神疾病患者大麻使用的数字干预措施综述

摘要

客观的

大麻使用障碍 (CUD) 与精神疾病和症状的风险升高有关，导致健康结果不佳并增加医疗费用。不幸的是，同时解决大麻使用和同时发生的精神疾病的干预措施的可用性有限。减少大麻使用的有针对性的数字干预措施可能对精神疾病患者有益。数字干预措施可以很容易地在许多临床场所传播和使用，包括门诊、住院、住院和社区精神科治疗机构。

方法

2021 年 4 月至 2021 年 6 月期间，对有关精神疾病患者减少数字大麻干预措施的文献进行了审查。文章来自 PubMed 和 PsycINFO 数据库。其中包括英语随机对照试验 (RCT)、可行性和可接受性研究、试点研究和已发布的方案。

结果

有大量证据表明，数字干预措施可以有效减少一般非临床人群的大麻使用。然而，很少有文献探讨对同时患有精神疾病的人的干预措施，其中大部分是针对慢性精神病患者量身定制的。

结论

针对同时发生的 CUD 和精神疾病，非常需要可访问且量身定制的数字干预措施。